FENNEC PHARMACEUTICALS INC

Rosty’s 10‑K sell‑off of 10,000 shares at $9.58 shows routine insider liquidity, not a sign of weakness, and keeps Fennec’s outlook steady for investors.

Insider trades at Fennec Pharma show routine liquidity management, not a bullish shift—executives maintain positions while funding R&D.

Insider buying at Fennec Pharmaceuticals signals management confidence in its drug pipeline—yet the company remains a high‑risk, high‑reward biotech. 140 characters

Fennec Pharmaceuticals’ CEO buys 16,695 shares, signalling strong insider confidence and potential price stabilization amid biotech volatility.

Fennec’s insider buying: Cioffi’s 4,700‑share option exercise shows leadership’s confidence amid strong sales growth and a bolstered balance sheet.

CEO Jeffrey Hackman’s recent 13,710‑share purchase signals growing confidence in Fennec Pharmaceuticals, amid a 7% weekly rally and strong insider buying.

Fennec Pharmaceuticals CFO’s latest insider buy signals long‑term confidence, hinting at a potential rebound amid market volatility and a strong oncology pipeline.